Learn More About the 2026 Summit
Oral TYK2 Treatment Envudeucitinib Shows Strong Phase 3 Psoriasis Results
Alumis Inc. has scored a major win in psoriasis drug development with its oral TYK2 inhibitor envudeucitinib, reporting positive outcomes from two Phase 3 clinical trials.
Sanofi’s Eczema Drug Amlitelimab: Mixed Phase 3 Results and What’s Next for Dermatology
Sanofi is pressing ahead with global filings for its experimental eczema medicine amlitelimab, despite a mixed reading from Phase 3 clinical trials.
New Hope in Alopecia Areata: Rezpegaldesleukin Shows Promise Despite Mixed Phase 2 Results
Autoimmune hair loss — alopecia areata — affects millions worldwide and has few durable treatment options.
Explore the Agenda to Discover the Clinical & Access Priorities Shaping Dermatology R&D in 2026
Explore a focused agenda of late-stage case studies, interactive workshops and peer-led discussions tackling clinical design, regulatory access, reimbursement and differentiated dermatology modalities.
Partner to Position Your Solutions at the Centre of Active Dermatology Pipelines
Partner with the summit to showcase your capabilities to senior pharma and biotech teams actively seeking support across biomarkers, imaging, clinical trials, manufacturing and formulation.
Join Biopharma Experts to Connect with the Decision-Makers Driving Dermatology Development Forward
Join 60+ senior leaders from pharma and biotech for high-value networking, candid peer exchange and relationship-building across late-stage development, access and launch in Europe.